Evidence map›Paper›PMID 40447542›Full record

ReviewSeminars in nuclear medicine2025

Advances in Endocrine Tumor PET Imaging Targeting CXCR4 and GLP-1.

Esther Mena, Liza Lindenberg, Peter Herscovitch, Samira M Sadowski, Peter L Choyke

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Esther MenaMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda MD. Electronic address: esther.menagonzalez@nih.gov.
Liza LindenbergMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda MD.
Peter HerscovitchPET Department, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda MD.
Samira M SadowskiSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda MD.
Peter L ChoykeMolecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda MD.

Funding

Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Molecular imaging has experienced significant advances in the areas of imaging probes and technology, enabling the detection of tumors at earlier stages and more accurately identifying extent of disease. To better characterize lesions, nuclear medicine modalities utilize molecular imaging agents targeting specific pathways and cell surface molecules to improve both sensitivity and specificity. In the field of endocrinology, tumors encompass a wide spectrum of aggressiveness ranging from indolent, well differentiated tumors to highly aggressive cancers. Thus, in recent years, new molecular imaging biomarkers have been developed for noninvasively assessing different types of hormone-producing tumors. For instance,

Indexed as

Endocrine Gland NeoplasmsPositron-Emission TomographyReceptors, CXCR4AnimalsHumansReceptors, CXCR4

Identifiers

PMID40447542
PMCPMC12313406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.